D&O

Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates

Retrieved on: 
Friday, March 8, 2024

JERUSALEM, March 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, today reported financial results and key business updates for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • JERUSALEM, March 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, today reported financial results and key business updates for the fourth quarter and year ended December 31, 2023.
  • Following our December 2023 financing, we expect to have sufficient cash to fund operations through the first half of 2025,” said Miranda Toledano, CEO of Entera.
  • Financial Results for the year Ended December 31, 2023
    As of December 31, 2023, Entera had cash and cash equivalents of $11.0 million.
  • Operating expenses for year ended December 31, 2023 were $8.9 million, as compared to $13.0 million for the year ended December 31, 2022.

Alpha Tau Medical Announces Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 7, 2024

We are also exploring the addition of new clinical trials in the U.S., based upon recent positive regulatory feedback.

Key Points: 
  • We are also exploring the addition of new clinical trials in the U.S., based upon recent positive regulatory feedback.
  • The Alpha DaRT procedure was deemed technically successful in all five cases, with Alpha DaRT sources successfully inserted into the target tumors.
  • Targeting completion of patient recruitment in the ReSTART pivotal U.S. multi-center trial in recurrent cutaneous squamous cell carcinoma in H2 2024.
  • The Company expects that this cash balance will be sufficient to fund operations for at least two years.

Fitell Corporation Announces First Half-Year Financial Results

Retrieved on: 
Tuesday, March 5, 2024

Management believes that the market will gradually recover, and the fitness and wellness industry in Australia is still promising in the long-term.

Key Points: 
  • Management believes that the market will gradually recover, and the fitness and wellness industry in Australia is still promising in the long-term.
  • In the three months ended December 2023, merchandise revenue increased $103,849 or 10.9% compared to the same period in 2022.
  • There were no sales of consumable products, and management plans to develop this business segment again whenever business opportunity arises.
  • Cost of goods sold was $1,275,967, representing a decrease by approximately $185,478, or 12.7% from the same period in 2022.

Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update

Retrieved on: 
Wednesday, February 28, 2024

WESTPORT, Conn., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported financial results for the fiscal quarter ended December 31, 2023.

Key Points: 
  • WESTPORT, Conn., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported financial results for the fiscal quarter ended December 31, 2023.
  • R&D costs increased slightly by approximately $0.1 million, or approximately 1%, from approximately $2.7 million in the Fiscal 2023 Quarter, to approximately $2.8 million in the Fiscal 2024 Quarter.
  • G&A expenses decreased by approximately $0.7 million, or approximately 35%, from approximately $2.0 million in the Fiscal 2023 Quarter, to approximately $1.3 million in the Fiscal 2024 Quarter.
  • The Company’s other pre-tax items of income and expense were substantially non-cash in nature and aggregated to approximately $44.9 million net expense in the Fiscal 2024 Quarter, compared to approximately $0.6 million net expense during the Fiscal 2023 Quarter.

Best’s Market Segment Report: AM Best Assigns Negative Outlook to U.S. Directors and Officers Insurance Segment; Notes Abundant Capacity, Decline in Demand

Retrieved on: 
Monday, March 4, 2024

AM Best has assigned a negative outlook to the U.S. directors and officers (D&O) market segment, citing growing competition as a key factor that has led to more capacity and lower pricing.

Key Points: 
  • AM Best has assigned a negative outlook to the U.S. directors and officers (D&O) market segment, citing growing competition as a key factor that has led to more capacity and lower pricing.
  • AM Best estimates that premium for full-year 2023 will reach $12 billion.
  • Concurrently, companies entering the market that are unencumbered by legacy claims continue to grow market share, which has resulted in highly competitive conditions with supply outpacing demand.
  • AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry.

Arbe Announces Q4 and Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 7, 2024

TEL AVIV, Israel, March 7, 2024 /PRNewswire/ -- Arbe Robotics Ltd. (NASDAQ: ARBE) ("Arbe"), a global leader in Perception Radar Solutions, today announced financial results for its fourth quarter and full year ended on December 31, 2023.

Key Points: 
  • TEL AVIV, Israel, March 7, 2024 /PRNewswire/ -- Arbe Robotics Ltd. (NASDAQ: ARBE) ("Arbe"), a global leader in Perception Radar Solutions, today announced financial results for its fourth quarter and full year ended on December 31, 2023.
  • Gross margin in Q4 2023 was a negative 54.5%, compared to a negative gross margin of 45.6% in Q4 2022.
  • Operating expenses in Q4 2023 were $11.9 million, compared to $14.0 million in Q4 2022.
  • 2023 Net loss included financial income of $3.4 million compared to $7.2 million of financial income in 2022.

Best’s Commentary: Despite Heightened Risks, Casualty Reinsurance Renewals See Modest Price Changes

Retrieved on: 
Thursday, February 15, 2024

The Best’s Commentary, “Despite Heightened Risks, Casualty Reinsurance Renewals See Modest Price Changes,” states that reinsurers also maintained underwriting discipline relative to volatile property covers, with attachment points, and terms and conditions unlikely to be relaxed any time soon.

Key Points: 
  • The Best’s Commentary, “Despite Heightened Risks, Casualty Reinsurance Renewals See Modest Price Changes,” states that reinsurers also maintained underwriting discipline relative to volatile property covers, with attachment points, and terms and conditions unlikely to be relaxed any time soon.
  • More frequent and severe weather events have resulted in multiple price increases for property catastrophe reinsurance over the past few years.
  • However, reinsurers remain hesitant to allocate more capital to these exposures until there are clearer indications that technical rate adequacy has been achieved.
  • The trade-off between property catastrophe reinsurance and casualty reinsurance was very much a factor during the latest renewal season, according to the report.

Diligent Launches Director & Officer Questionnaire Time-Saving Templates, Reducing Regulatory Risk and Ensuring Data Security

Retrieved on: 
Friday, February 2, 2024

NEW YORK, Feb. 2, 2024 /PRNewswire/ -- Diligent, a leading GRC SaaS company, today announced the launch of Director & Officer (D&O) questionnaire templates within the Diligent One Platform. Launched in partnership with Latham & Watkins, a leading global law firm with one of the largest public company representation practices in the world, the questionnaire templates will enable organizations to seamlessly collect information required for disclosure in the Annual Report on Form 10-K and Proxy Statement that is filed with the US Securities and Exchange Commission (SEC).

Key Points: 
  • "Building questionnaires from scratch to collect the right information from board members and executives to meet regulatory requirements takes more time than it should," said Nithya B. Das, Chief Legal & Administrative Officer at Diligent.
  • "Through partnerships with leading law firms like Latham & Watkins, we're thrilled to help governance teams reduce regulatory risk, develop questionnaires faster and ensure a secure experience every step of the way."
  • A completely customizable format with questions covering a director or officer's background, compensation, skills, qualifications, and diversity, among other areas.
  • Latham's focus on innovation is a hallmark of our firm, and the collaboration with Diligent exemplifies our innovative, market-leading practice."

International Towers by Zurich adds Side A-only D&O insurance policy

Retrieved on: 
Thursday, February 1, 2024

SCHAUMBURG, Ill., Feb. 1, 2024 /PRNewswire/ -- Zurich American Insurance Company, a member company of Zurich North America, has added a standalone Side A Directors & Officers insurance coverage option for U.S.-based multinational companies with non-U.S. board members and officers. The new Side A-only D&O policy, called International Towers by Zurich Executive Universal Select, addresses a critical need for non-U.S. directors and officers: It helps protect their personal financial assets if they are faced with a management liability lawsuit and their company cannot cover their legal costs due to local laws, court orders or other reasons. These are known as non-indemnifiable losses.

Key Points: 
  • The new policy, the latest addition to the award-winning International Towers by Zurich suite of D&O solutions, goes beyond fulfilling this essential need.
  • The International Towers by Zurich Executive Universal Select policy includes the following:
    A Master Policy issued to the U.S. parent that covers Side A D&O risk for non-U.S. directors and officers only.
  • The International Towers by Zurich Executive Universal Select policy provides a separate limit for losses outside the U.S.
    Another differentiator is that International Towers by Zurich policies can be purchased from Zurich without Zurich being the Primary or Lead Side A carrier on the customer's U.S. D&O tower.
  • International Programs by Zurich (IPZ) has earned a reputation for innovative solutions, winning three awards from Business Insurance in the past two years, including one in 2022 for the original International Towers by Zurich .

CVRx Reports Fourth Quarter and Full Year 2023 Financial and Operating Results

Retrieved on: 
Thursday, January 25, 2024

Revenue was $11.3 million for the three months ended December 31, 2023, an increase of $4.1 million, or 58%, over the three months ended December 31, 2022.

Key Points: 
  • Revenue was $11.3 million for the three months ended December 31, 2023, an increase of $4.1 million, or 58%, over the three months ended December 31, 2022.
  • HF revenue units in the U.S. totaled 330 and 193 for the three months ended December 31, 2023 and 2022, respectively.
  • HF revenue in the U.S. totaled $10.2 million and $6.0 million for the three months ended December 31, 2023 and 2022, respectively.
  • As of December 31, 2023, the Company had a total of 178 active implanting centers, as compared to 159 as of September 30, 2023.